Natural Product (NP) Details
| General Information of the NP (ID: NP5733) | |||||
|---|---|---|---|---|---|
| Name |
Daphnetin
|
||||
| Synonyms |
daphnetin; 7,8-Dihydroxycoumarin; 486-35-1; Daphnetol; 7,8-Dihydroxy-2H-chromen-2-one; 7,8-Dihydroxy-2H-1-benzopyran-2-one; 7,8-dihydroxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-; 7,8-DIHYDROXY-2H-BENZOPYRAN-2-ONE; UNII-XC84571RD2; C9H6O4; TCMDC-125839; COUMARIN, 7,8-DIHYDROXY-; CHEMBL244948; CHEBI:17313; XC84571RD2; 7,8-Dihydroxycoumarin (Daphnetin); MFCD00016977; NSC633563; SMR001230713; SR-01000075820; EINECS 207-632-8; NSC 633563; BRN 0009372; 7,8-DIHYDROXY-CHROMEN-2-ONE; 1,8-Dihydroxycoumarin; PubChem13303; 7,8-dihydroxy-coumarin; ACMC-1AKCA; SpecPlus_000864; Spectrum3_000784; Spectrum4_001254; Lopac-D-5564; Lopac0_000330; Oprea1_044324; BSPBio_002488; KBioGR_001808; 5-18-03-00211 (Beilstein Handbook Reference); MLS002153288; MLS006012039; DivK1c_006960; SCHEMBL128212; 7,8-Dihydroxycoumarin, 90%; KBio1_001904; KBio3_001708; ZINC57753; 7,8-bis(oxidanyl)chromen-2-one; DTXSID00197560; HMS3261A21; HMS3656G16; 7,8-dihydroxy-1-benzopyran-2-one; HY-N0281; Tox21_500330; ANW-43482; BBL036425; BDBM50206006; CCG-39736; CD0136; HSCI1_000053; s2554; STL558976; 7,8-Dihydroxy-2H-chromen-2-one #; AKOS000277449; LP00330; MCULE-9549774136; NSC-633563; PB17055; SDCCGSBI-0050318.P003; 7,8-Dihydroxycoumarin, >=97%, powder; NCGC00015349-01; NCGC00015349-02; NCGC00015349-03; NCGC00015349-04; NCGC00015349-05; NCGC00015349-06; NCGC00015349-12; NCGC00093770-01; NCGC00093770-02; NCGC00261015-01; AK170408; AS-63138; DB-051567; CS-0008778; D4001; EU-0000106; EU-0100330; FT-0603132; N1567; ST50308908; SW000346-2; V0328; C03093; D 5564; Q-1224; 2H-1-Benzopyran-2-one, 7,8-dihydroxy- (9CI); 486D351; A827573; AE-641/02519040; Q-100543; SR-01000075820-1; SR-01000075820-2; BRD-K61269089-001-01-4; BRD-K61269089-001-02-2; Q27102315
Click to Show/Hide
|
||||
| Species Origin | Euphorbia ... | Click to Show/Hide | |||
| Euphorbia | |||||
| Disease | Osteoporosis [ICD-11: FB83] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C9H6O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC(=C(C2=C1C=CC(=O)O2)O)O
|
||||
| InChI |
1S/C9H6O4/c10-6-3-1-5-2-4-7(11)13-9(5)8(6)12/h1-4,10,12H
|
||||
| InChIKey |
ATEFPOUAMCWAQS-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 486-35-1
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | GABPA | Molecule Info | ||
| Up-regulation | Expression | HMOX1 | Molecule Info |
Pathway MAP
|
||
| Experimental
Result(s) |
Daphnetin inhibited cisplatin-induced nephrotoxicity by inhibiting NF-KappaB and activating Nrf2 signaling pathways. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [3] | |
| KEGG Pathway | Protein processing in endoplasmic reticulum | Click to Show/Hide | ||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| WikiPathways | Oxidative Stress | Click to Show/Hide | ||
| 2 | Transcriptional activation by NRF2 | |||
| 3 | NRF2 pathway | |||
| 4 | Nuclear Receptors Meta-Pathway | |||
| 5 | Aryl Hydrocarbon Receptor Pathway | |||
| 6 | Mesodermal Commitment Pathway | |||
| 7 | Aryl Hydrocarbon Receptor | |||
| 8 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 9 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
